HPV, STI and AMR in West Africa: estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions
HPV, STI and AMR in West Africa: estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions
批准号:
MR/W002116/1
负责人:
Ed Clarke
金额:
$65.3万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
United Nations Sustainable Development Goal 3 (SDG3) sets ambitious targets for improving health and wellbeing globally by 2030. This includes targets for reducing the number of people dying early from cancer, and the number of newborns dying for preventable reasons. It includes targets for dramatically reducing the number of hepatitis B and hepatitis C infections, and for stopping all cases of HIV being passed from a mother to baby. The goal also calls for universal access to sexual and reproductive health care. Many of these areas disproportionately impact on the health and wellbeing of women and make gender inequality worse. This conflicts with the aims of SDG5 which aims to reduce such inequality.If the targets for women in The Gambia and other parts of West Africa are to be achieved, a dramatic increase in progress is essential. A recent review highlighted that one of the main reasons that progress has been too slow so far, is a lack of reliable information on the burden of given health conditions. This was found to be a particular problem in West Africa compared to other parts of the world. The proposed survey will specifically address this and aims to drive improvements in key areas for the health and wellbeing of women in The Gambia and other parts of West Africa as follows:Human papillomavirus (HPV), which is sexually transmitted, causes cervical cancer, one of the most common causes of cancer death in women in Africa. There is already a vaccine against HPV which has been shown to be very good at preventing cancer in women in high income countries. The vaccine is going to be introduced in The Gambia and it is now essential to be able to monitor how good it is in West Africa too. Measuring how much HPV females in The Gambia have before the vaccine is introduced is critical for this and is an important aim of the survey. It may be that there are better, or easier, ways to give HPV vaccines and that improved vaccines become available too. The information from the survey is essential if we are to predict and measure this and ultimately reduce the number of women dying early from cervical cancer in West Africa.Other sexually transmitted infections (STIs), including syphilis, gonorrhoea, and chlamydia, are important causes of preventable deaths in newborns, of stillbirths, of infertility and of other sexual and reproductive health problems. For infections like gonorrhoea, resistance to many antibiotics is increasing too in some parts of the world. We do not know how big a problem this is in West Africa. The survey will measure how common STIs and antibiotic resistance are in females in The Gambia. This information will first, improve the way we treat STIs in The Gambia and other parts of West Africa and second, drive the development of new tests for the infections, and new vaccines to prevent them.Hepatitis B and C are the leading causes of liver cancer in West Africa. Hepatitis B is preventable by vaccination and providing the vaccine to newborns in the first 24 hours of life prevents the infection being transmitted from mother to baby. Medicines that can cure hepatitis C are available. It is also possible to prevent HIV being transmitted from mother to baby. To do this it is essential the mother knows she has the infection during pregnancy and that the baby is given medicines when it is born. The survey will measure how common these three infections are in women of childbearing age. It also aims to identify those factors in the Gambian health system that mean the effective prevention and treatment strategies which exist are either not available or not implemented correctly.In summary, information from the planned survey aims to accelerate progress towards SDG3 in key areas and thus will have much needed positive impact on the health and wellbeing of women in West Africa.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ICF: Unmanned aerial vehicles ('drones') for sustainable vaccine research and improving equity in vaccine delivery: a feasibility study in The Gambia
-
批准号:MR/X011771/1
-
项目类别:Research Grant
-
资助金额:$12.84万
-
财政年份:2022
-
负责人:Ed Clarke
-
依托单位:
A non-inferiority trial to assess the safety and immunogenicity of yellow fever vaccine dose sparing strategies for campaign and programmatic use
-
批准号:MC_EX_MR/R006148/1
-
项目类别:Research Grant
-
资助金额:$140.08万
-
财政年份:2017
-
负责人:Ed Clarke
-
依托单位:
A randomised, observer-blind, non-inferiority trial to evaluate alternative human papillomavirus vaccination schedules in young females in West Africa
-
批准号:MC_EX_MR/N006070/1
-
项目类别:Research Grant
-
资助金额:$211.01万
-
财政年份:2015
-
负责人:Ed Clarke
-
依托单位:
A randomised controlled trial to evaluate the effect of maternal or neonatal pneumococcal conjugate vaccination on pneumococcal carriage in early life
-
批准号:MC_EX_MR/M007529/1
-
项目类别:Research Grant
-
资助金额:$180.51万
-
财政年份:2014
-
负责人:Ed Clarke
-
依托单位:
国内基金
海外基金
登录
查看更多内容
STI、TMAD及IBS评价降脂消斑片对家兔冠状动脉粥样硬化模型心肌硬度及心功能影响的研究
-
批准号:2025JJ80968
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:王月爱
-
依托单位:
新型小分子FLT3抑制剂STI-8591在FLT3突变急性髓系白血病中的应用及机制研究
-
批准号:MS25H080016
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:张仪
-
依托单位:
语言声房间和厅堂的语音传输指数(STI)评价阈值研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:54万元
-
批准年份:2022
-
负责人:祝培生
-
依托单位:
超声STI多层分析技术结合负荷心肌声学造影评价兔ATP药物后适应模型及生物机制探讨
-
批准号:81571680
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:任敏
-
依托单位:
联合应用QSM和STI定量监测多发性硬化脑白质病灶动态演变及其成像机制研究
-
批准号:81501445
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2015
-
负责人:曹玮
-
依托单位:
STI结合MCE评价缺血后适应和药物后适应的兔心肌保护作用及其机制研究
-
批准号:81201093
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:任敏
-
依托单位:
从STI与Cbfa1及破骨相关基因表达的关系探讨彝药恒古骨伤愈对骨质疏松性骨折愈合质量的影响
-
批准号:30860389
-
项目类别:地区科学基金项目
-
资助金额:27.0万元
-
批准年份:2008
-
负责人:赵宏斌
-
依托单位:
通过对TPL的化学修饰、结构优化构建高效低毒的靶向STI571抵抗性Bcr-Abl、c-KIT酪氨酸激酶的小分子抑制物
-
批准号:90713036
-
项目类别:重大研究计划
-
资助金额:50.0万元
-
批准年份:2007
-
负责人:潘景轩
-
依托单位:
胃肠道间质瘤STI571耐药优势克隆的形成及继发耐药的分子机制研究
-
批准号:30700809
-
项目类别:青年科学基金项目
-
资助金额:16.0万元
-
批准年份:2007
-
负责人:刘晓红
-
依托单位:
慢性粒细胞白血病STI571耐药分子机制和有效替代治疗策略的研究
-
批准号:30371612
-
项目类别:面上项目
-
资助金额:20.0万元
-
批准年份:2003
-
负责人:任汉云
-
依托单位: